aXichem AB (publ), publishes its interim report for the first quarter of 2024 on Thursday, May 23, 2024. On the same day at 4:00 p.m., the company invites you to a teleconference with CEO Torsten Helsing.
After the conference, there will be a question-and-answer session. Please note that the presentation is held in Swedish. It is possible to follow the conference via computer or mobile devices.
To register for the web conference, please register via the following link:
The information was submitted, through the care of the contact person below, for publication on 17 May 2024, at 13:00 CET.
Company contact: Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com
About aXichem aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
